HRS 6209
Alternative Names: HRS-6209Latest Information Update: 21 Aug 2024
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action Cyclin-dependent kinase 4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 15 Aug 2024 Jiangsu HengRui Medicine plans a phase I/II trial for Breast cancer (Combination therapy, Late-stage disease, Unresectable, Metastatic disease) in China in August (NCT06555068)
- 04 Dec 2023 Phase-I clinical trials in Solid tumours (Late-stage disease) (unspecified route), prior to December 2023 (Jiangsu HengRui Medicine pipeline, December 2023)
- 30 Mar 2023 Jiangsu Hengrui Medicine plans a phase I trial for solid tumours (Late-stage disease) in China in April 2023 (NCT05781048)